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Necessity for a novel form of interactive
conference
Clinical trials are the foundation for the advancement of
medical research, but they are also complex, time con-
suming and expensive. To ensure scientific validity, clini-
cal trials must record large amounts of data on health
and treatment of a carefully selected group of patients or
trial participants. That is why a robust and highly flexible
IT infrastructure that permits rapid reconfiguration to
support different trials while maintaining consistent data
models is needed to ensure that clinical data can be
shared and used for analysis. Recently, EU projects, like
TRANSFoRm, p-medicine, EHR4CR and BioMedBridges,
are creating advanced clinical research information sys-
tems consisting of sets of tools that assist in the prepara-
tion and conduct of clinical trials and the re-use of care
data for research purposes. These tools are also able to
assemble data from heterogeneous sources to answer
complex research questions, including functions for data
mining and support of research process workflows to
meet the needs of translational and personalized medical
research [1].
Because the translation of biomedical discoveries into
clinical applications is an aim of the EU Commission,
clinical research support is expected to be a major com-
ponent of EU funded projects [2]. In this context, the
EU Framework Program 7 (FP7, http://ec.europa.eu/
research/fp7/index_en.cfm) has promoted translational
research, the so-called ‘from bench-to-bedside’
approach, that is expected to have practical benefits and
improvements of the quality of life for patients. In this
context, it is planned that many of the tools developed
in ESFRI (European Strategy Forum on Research Infra-
structures) and IMI projects will be used by ECRIN, the
European Clinical Research Infrastructures Network [3]
to advance clinical trials. To provide information on
these new research tools and to evaluate their usability
for the clinical research community, the CRI Solutions
Day was organised by ECRIN together with other EU-
funded projects (TRANSFoRm, EHR4CR, p-medicine,
BioMedBridges and ECRIN-IA) providing interactive
“hands-on” sessions to allow visitors to see these tools
in action. The necessity for such a solutions day was
based on the experience of ECRIN that the conven-
tional, class room style presentation of research tools is
not sufficient to demonstrate comparability and usability
to many researchers. Thus, presenters from academia,
research infrastructures and EU projects presented their
developments with interactive sessions embedded in a fra-
mework of presentations and joint discussions. The CRI
solutions day took place at Heinrich-Heine University
Düsseldorf, in Düsseldorf, Germany, 26-27 May 2014.
A new landscape for modern clinical research
After the welcoming speech by the Rector of Heinrich-
Heine University Michael Piper (Heinrich-Heine Uni-
versity Düsseldorf), Christian Ohmann (KKS and
ECRIN) opened the conference with an overview on the
current developments in clinical trials and the influence
that translational medicine and data-driven science may
have on clinical trials progress (Figure 1). Because still
only very few innovations have managed to get into clini-
cal routine use, the need for change in drug development
is evident. It was proposed that data driven research will
be able to discover structures in big data and lead to pre-
dictions avoiding the detour through hypothesis-driven
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research and clinical trials. One should ask, if it is possi-
ble to apply a unified modeling approach to health care,
and improve the effectiveness of health care with data-
driven medicine using for example genome-wide research
data. But data-intensive science may rather complement
conventional methods and thus be used to increase
potential benefits following clinical trials to demonstrate
efficacy and efficiency. For example, it may be possible to
Figure 1 Key notes speakers and EU project heads (from top to bottom: Christian Ohmann, Michael Piper, Ann Martin, Brendan Delaney,
Norbert Graf, Brecht Claerhout, Jacques Demotes, Stephanie Suhr).
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use big data to identify subgroups of patients that will
profit from a treatment; or test oncological drugs to
receive a better therapeutic prediction. Whatever the
case, the clinical trials landscape will change; EHR data
will be used for feasibility and patient recruitment.
Increasingly predictive biomarkers will be analysed to
determine outcome, increase power and to stratify
patients in clinical trials.
Ann Martin (IMI) explained the Innovative Medicines
Initiative (IMI). IMI is Europe’s largest public-private
initiative of collaborative research projects aiming to
speed up the development of better and safer medicines.
About 2 billion Euros are being spent with 50% of the
sum paid by the EU and 50% by the pharma industry.
It covers until to date 11 calls for proposals resulting in
59 collaborative projects. About 130 Mio Euro is being
spent only for improved knowledge management, cover-
ing integrated biomedical data platforms and tools for
data management and big data (e.g. eTOX, Open-
PHACTS, EMIF, eTRIKS). Two important aspects of all
EU projects are aspects of descriptive metadata and data
quality / data governance. Interoperability must be estab-
lished by the implementation of standards. IMI II has
begun with 3.45 billion Euro and employing H2020 rules,
with the first call starting about July 2014. Because IMI
projects are focusing on -omics (research including geno-
mics, proteomics or metabolomics), genomics and
patient data, the platforms and tools discussed in this
solutions day are of importance for IMI projects, too.
Session 1: EU funded projects with participation
of ECRIN
Wolfgang Kuchinke (Heinrich-Heine University,
Düsseldorf) described the role ECRIN plays in the EU
projects TRANSFoRm, p-medicine, BioMedBridges and
EHR4CR and how ECRIN plans to employ tools devel-
oped in these projects. ECRIN participated in developing
information models, data models and ontologies, pro-
moted the use of standards and created legal and ethical
frameworks for these projects. Most of the developed
tools will be provided as services and these services have
to be integrated into the ECRIN infrastructure of clinical
trial support. This integration must proceed on three
levels: technical level, process level and business level.
For ECRIN, the integration of data stored in hospital
information systems (HIS) and EHR for research pur-
poses will be a special challenge, requiring the collabora-
tion of local hospitals, EHR and HIS vendors, patients,
investigators, ECRIN EU Correspondents and clinical
trials units (CTU) staff.
Brendan Delaney (King’s College, London) explained
the importance of the concept of the Learning Health
Care System (LHS) for the TRANSFoRm project [4].
Enabling the use of primary care data for research, the
final aim of TRANSFoRm is the improvement of patient
health and safety. TRANSFoRm consists of three parts:
first, support of epidemiological genotype-phenotype stu-
dies; second, support for randomized clinical trials
(RCT), and third, decision support for the physician.
Pilot studies with the tools developed in TRANSFoRm
will begin soon. EHR data sources will be analysed using
the Query Workbench. The randomized clinical trial will
employ an eCRF integrated in an EHR that provides a
trigger mechanism for indicating to the physician eligible
patients. To bridge different clinical concepts between
the usage of clinical data in care and research, ontologies
were implemented in the tools (CDIM). In addition, a
full data provenance trail is ensured, and standards, ter-
minologies and archetypes are combined. To illustrate
the recent developments of IT in clinical research; Bren-
dan Delaney used the picture of the evolution of the
human brain. The legacy systems together with asso-
ciated terminologies, like HL7, CDISC ODM represent
the reptilian brain; the interactive and semantic aspects
of IT solutions, like models and archetypes, are repre-
sented by the limbic brain and the medical reasoning
based on ontologies is represented by the most evolved
form, the neocortex.
Norbert Graf (USAAR) presented results and chal-
lenges of the p-medicine project [5], a clinically driven
project about personalized medicine in oncology with 19
partners. The p-medicine platform serves knowledge dis-
covery, including genetic and phenotype data. It allows
the assessment of analytical results in context to ensure
that patients obtain an individualized therapy. Thus
patient empowerment must play an important part in the
project. Tools, models, means to ensure re-use of data,
and data warehouses are enclosed by a security frame-
work, consisting of data anonymisation, contracts with
users and consents given by data donors. Clinicians will
be the users of the tools, but p-medicine will also ensure
that more patients are enrolled in personalized medicine
trials.
Brecht Claerhout (Custodix) presented EHR4CR [6],
an IMI project that will enable the re-use of hospital data
for optimising clinical trials conduct. The need for the
project results in the fact that drug innovation has
become too slow and too expensive (about 1.2 billion
Euro is needed to develop a drug from a chemical entity).
Most important, 50% of delays in clinical trials come
from inefficient patient recruitment, because clinical
trials often fail to enrol enough patients. EHR4CR has
four use cases for EHR data re-use: optimizing protocol
feasibility, faster patient recruitment, improvement of
study conduct by pre-filling eCRFs and finally the capture
of adverse events (AE). The services developed will access
real clinical trials information by running queries at dif-
ferent clinical sites that compare if criteria are met. This
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procedure will be able to speed up recruitment by giving
physicians and investigators means to search for eligible
patients. The EHR4CR project is characterized by an
open architecture, a service platform, use of standards
and is open to different semantic layers. It has now
reached the testing phase of its pilots.
Jacques Demotes (ECRIN) presented ECRIN-IA and
concentrated on the project’s data management aspects.
ECRIN has become an ERIC (European Research Infra-
structure Consortium), a legal structure with now 5
countries involved, and 4 other countries that will join
soon. ECRIN-IA is about the structuring of user commu-
nities for nutritional research, rare diseases and medical
devices. Data management is part of ECRIN-IA and
started in the previous project with a large survey of all
ECRIN centres [7]. This survey showed that data man-
agement solutions for clinical trials are very heteroge-
neous and differences in quality standards exist at data
centres. What ECRIN needs is a system easy to use in all
ECRIN data centres that is cost effective to implement
and extensible. Addressing the need for quality standards
in clinical data management, a certification program for
ECRIN data centres was developed covering GCP com-
pliance and ECRIN requirements. A suitable data man-
agement solution (VISTA) is being built by EORTC
according to ECRIN specifications. VISTA will be avail-
able at low cost for academic institutions and for ECRIN.
In addition, ECRIN plans to develop a clinical trials out-
come database that will store core data sets of outcome
measures of ECRIN trials to enable further meta-analysis
after the end of the trials.
Stephanie Suhr (BioMedBridges) presented BioMed-
Bridges, a large EU project in which 21 partners repre-
sent 10 new European research infrastructures covering
research domains from bioinformatics and biobanking to
translational research. Recently, emerging infrastructures
for systems biology and microbiology have also joined.
The aim of BioMedBridges is to integrate existing islands
of data sources that harbour clinical data, biological data,
and images in different research infrastructures by the
means of data bridges and services. With the help of
REST services and a data security framework, data pre-
viously isolated will become discoverable for researchers.
Data integration will take place on the technical level
(standards) and on the process level by REST services
and by semantic web techniques. Three tools developed
by BioMedBridges were presented at the workshop,
CTIM, MOLGENIS and XNAT. In addition, LAT was
developed, a tool that precedes the data discovery process
and supports researchers in identifying legal and ethical
risks associated with the process of data access or data
sharing.
The following joint discussion focused on the provi-
sion and the sustainability of the multitude of tools
developed in EU projects. Because these tools are public
developments, they should be freely shared over the web
(Ann Martin). In this context all speakers confirmed
the future public availability of the tools developed.
Stephanie Suhr affirmed that all deliverables and tools
developed in BMB will be public. Though, ECRIN deli-
verables are public, VISTA will not be open source and
usage will be accompanied by a non-profit fee. For
the p-medicine project, too, all tools will be Open
Source (Norbert Graf). All deliverables of TRANSFoRm
are publicly available; and TRANSFoRm tools will be
provided as Open Source for free usage with accompa-
nying documentation. EHR4CR too will make deliver-
ables publicly available.
A discussion followed about the role that a certification
procedure can play in infrastructures and for tool employ-
ment. A certification of tools could ensure the GCP com-
pliance of usage or the observance of regulations, like the
ones for data protection. ECRIN has developed a certifica-
tion procedure with an independent certification board for
clinical data centres. During the phase of certification
development the German Accreditation Agency advised
ECRIN not to start with establishing an accreditation, but
to create a certification process (Christian Ohmann).
Norbert Graf explained that p-medicine has launched a
special legal entity to ensure its sustainability: STaRC. All
tools in p-medicine must be validated for GCP compliance
and usability by clinicians. But an important aspect is that
the validation and certification of tools that will be used in
clinical trials is out of scope of EU projects. In addition,
lawyers are needed to set up contracts between providers,
data owners and users. For BioMedBridges, Stephanie
Suhr explained, sustainability is built already into the pro-
ject by the participating research infrastructures which are
themselves sustainable entities.
Conference participants noticed similarities in tool
development. For example, TRANSFoRm and EHR4CR
have developed tools/services with several aspects in
common, like the search for patient’s inclusion and
exclusion criteria. It was asked, if both projects will not
develop tools or deliverables together. But the require-
ments underlying these projects are quite different.
Brendan Delaney explained that for TRANSFoRm the
inclusion / exclusion criteria model is based specifically
on PCROM and BRIDG, and both models determine
how the query workbench can operate and how
the queries are created. Design of queries is based on
LexEVS terminology [8], and is linked over data node
connectors with ontologies. TRANSFoRm is a distribu-
ted infrastructure and allows that data stays where it is.
In contrast, according to Brecht Claerhout, the EHR4CR
project starts from a clinical model, ETL to the data
warehouse. All queries are built upon a specific informa-
tion model (blue model and ECLECTIC) and the
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concepts of the information model are again mapped to
queries.
Break out session 1
In this breakout session (Figure 2), tools for clinical data
management (OpenClinica, ObTiMA, VISTA), tools for
bridging experimental and clinical research data (tranS-
MART, MOLGENIS, i2b2), and tools to integrate EHR
data for clinical research (Feasibility Service, Patient
Screening Tool, Recruitment and Feasibility Tools) were
presented and discussed.
Break out session 2
In the second breakout session (Figure 2), additional
tools for clinical data management (Functional eCRF,
mobile eHealth Solution), imaging tools for clinical
research (XNAT imaging pipeline, DoctorEye), and tools
for biobanking in clinical research (p-BioSPRE, Biobank-
ing Catalogue, BBMRI Catalogue) were presented and
discussed.
Panel discussion: what to do with all these tools?
In the previous breakout sessions important new tools to
move clinical research towards clinical trials in transla-
tional and personalised medicine were presented. The
overall impression is that the process of simple data col-
lection has become insufficient for clinical research and
study feasibility and patient recruitment has to be sup-
ported; EHR data, mobile eHealth data, biobank data and
data warehousing solutions have all to complement the
data collection process. Töresin Karakoyun pointed out
that for clinical research and data collection the ability
for cooperation has become of decisive importance. Thus
cooperation between EU projects and between research
infrastructures should be increased. While projects and
infrastructures are often aware of the existence of tools
developed elsewhere, improved cooperation capabilities
should enable the exchange of resources and people as
carriers of expertise between projects and infrastructures.
In this way, researchers will be enabled to find the best
solution and the best tool for their research. Users of
tools and tool developers should learn more efficiently
from each other. The ESFRI infrastructures may work
better together through BioMedBridges. As a first step,
BioMedBridges will create a repository of all tools, docu-
ments, sources of the member research infrastructures.
The validation and certification as a necessary condition
for sustainability is far from easy requiring the creation of
a large amount of documents for system validation, like
requirements specifications, functional specifications, and
user specifications. This leads to the issue that in the aca-
demic world the process of software development is not as
clean and precise as in industry. For example, tool devel-
opment is often an integrative part of a research project,
as a result of which requirements become a moving target.
Thus, often no frozen version of a tool is available for its
validation. Once one has decided to freeze tool develop-
ment for the validation / certification, research still goes
on resulting in new requirements and changes in tool
development. Norbert Graf clarified the need for certifica-
tion of the tools developed in academia. The ability for
certification depends also on the way projects and their
developed tools are funded. As a consequence, the EU
should provide funds to help projects to move into sus-
tainability. But to provide tools as Open Source is not an
easy solution either (Christian Ohmann); because Open
Source, too, needs support, services, and regular updates,
requiring somebody who pays for the sustainability of
Open Source. We are now at a point, where the gap
between pure research focusing on new problems and
publications and business focusing on the generation of
money has to be bridged for the EU projects. Projects
must now be helped to move from a research approach to
a product development approach.
Jacques Demotes turned the discussion to the user
communities for the developed tools. IT experts are con-
cerned that tool development is not driven by the user
communities. For example, clinical trials representatives
have specific needs but cannot develop tools by them-
selves. Thus, as a first step priorities and strategies should
be defined for the clinical trials communities. Although
user requirements for clinical data management systems
(CDMS) exist in ECRIN, they cover only the basic aspects
of data management. But CDMS requirements should
consider new developments in clinical trials, like the
involvement of imaging, biobanking and genome data.
Here new tools are necessary and must be integrated in
existing clinical data management processes. In addition,
tools that are employed for clinical trials must be system
validated for GCP compliance, requiring specifications
for the tools that cover these new fields of use. As a con-
sequence, ECRIN standard requirements that have been
developed for the certification of ECRIN data centres
should be extended accordingly. In addition, the patient
point of view must be considered for clinical trials more
strongly; patients will tell us more and will give us more
data. On the other hand, patients should be able to
decide how their data and biosamples should be accessed
and used, and how the right informed consent is
employed.
Conference participants recognised a competitive situa-
tion between the tools shown; for example, the tools
ObTiMA, OpenClinica, VISTA support data management
in clinical trials, whereas tranSMART and MOLGENIS
are data warehouse based solutions. It was suggested to
increase the transparency of developments and improve
the exchange of tools, information, as well as source code
created in different projects. Norbert Graf recommended
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building tools in a modular fashion, like it is done in p-
medicine, and with standardized interfaces. Ontologies
should be able to link directly to items. In this way,
researchers will be able to select and assemble appropriate
modules of different tools for their research question.
Often not everybody needs all functionality available. This
idea found support in the conference. Tools may come
and go, but the focus of software development should be
on standardized interfaces and data standards. One impor-
tant standard in this context is IHE (Integrating the
Figure 2 Impressions from the break-out and software demonstration sessions.
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Healthcare Enterprise), providing specific profiles for data
retrieval. Standards are able to bring different tools
together, like in the case of CDISC ODM, a data exchange
standard that can be used to integrate different CDMS to
be used in single clinical trial [9]. Töresin Karakoyun
pointed out that the area of processes should not be for-
gotten, because processes are often still far from being
clearly defined, like it is the case of the workflow for per-
sonalised clinical trials.
ECRIN and data in multinational clinical trials
Jacques Demotes (ECRIN) was looking forward to identi-
fying the challenges that are encountered by clinical trials
infrastructures. For clinical trials addressing innovative
health products, exploration of new indications for exist-
ing drugs, comparative assessments of efficiency and safety
of approved healthcare strategies, new infrastructure solu-
tions are necessary that need collaboration between indus-
try-funded and non-industry funded approaches. It is the
lack of funding and the missing infrastructures that are
the reason why only 3% of non-industry funded trials are
international. ECRIN-ERIC is a combination of national
networks of CTUs with national organizational points by
EUCos (ECRIN European Correspondents). Employing
this infrastructure, ECRIN provides all kind of services,
like assessment of feasibility, logistic, contract develop-
ment, coordination with ethics committees, site monitor-
ing, etc. IT should enable researchers to better use health
data for clinical trials, avoiding any duplication in data col-
lection. But only a small number of patients is actually
being enrolled to participate in clinical trials or to form
part of a cohort study. The systematic use of health data
for research, including the integration of registries,
cohorts, and clinical trials nested in cohorts, international
cooperation in non-commercial clinical trials must be
facilitated by establishing national / regional / global net-
works of co-operation in clinical science accompanied by
increased patient involvement in the clinical trial process.
To support these objectives, ECRIN expects that IT should
improve the access to clinical data (supporting data trans-
parency and making patient-level data available for meta-
analysis), enable up-to-data analysis of all different types of
clinical data (the ability of meta-analysis should be manda-
tory), provide suitable anonymised patient data for analysis
(for example, retrieval of aggregated data sets, support of
interoperability by using standardized outcome measures,
and by improving the integration of CRF data with high
throughput patient data in clinical trials (genomics, pro-
teomics data).
In the subsequent discussion growing concerns in the
research infrastructure community were addressed that
have to do with the fact that research conduct is changing
from research done by small teams of post docs to large
anonymous teams in big projects. As a consequence,
collaboration, contribution and the authoring rules have
become complex and often unclear; research contribution
cannot be based solely on authorship anymore.
A first step to increase transparency in clinical research
is to make the data collected by CRFs public, not only the
summaries of results and eligibility criteria. But this must
be followed by providing access to the study protocol, and
additional data like trial performance data. Access to all
clinical trials data requires sophisticated access policies, to
prevent any misuse of data (e.g. the prevention to identify
research participants), as well as data provenance and a
complete audit trail.
Session 2: translational research projects and
their tools for clinical research
John Overington (EU Openscreen) presented the EU
Openscreen infrastructure that combines chemistry with
biology and consists of national content collection centres.
EU Openscreen is a distributed infrastructure enabling
trans-national access for the development of bioactive
small molecules. All databases are open access; and addi-
tional screening centres with high-end equipment exist.
Recently, an ERIC for EU Openscreen is being negotiated.
EMIF was introduced by Alvaro Cortes (EMIF). EMIF
is an IMI project with the aim to develop a common infor-
mation framework of patient-level data to facilitate access
to diverse medical and research data sources. It started in
January 2013 with 48 partners. Because it provides access
to individual data sources and tries to enhance already
existing data sources, EMIF can be seen as a federation of
databases; whereby each data source retains full control
over its data. Database owners are supported by the provi-
sion of means for anonymisation / pseudonymisation,
tools for linking ontologies and by support of semantic
interoperability.
Anka Bucur (Phillips) introduced the INTEGRATE
project dealing with integrative cancer research with the
aim of facilitating clinical research to improve the treat-
ment of cancer patients. INTEGRATE focuses on using
knowledge sharing for patient recruitment. Recent use
cases are in breast cancer, but the solution developed will
be applicable to all disease domains by providing a seman-
tic interoperability platform. Tools for patient screening
and pathology review were shown in the hands-on ses-
sions during this workshop. An additional tool deals with
cohort selection by providing means for filtering data,
querying databases, and visualization of selected cohorts.
Jan-Willem Boiten (TraIT) presented issues of transla-
tional research. The TraIT project develops an IT infra-
structure for translational research with the aim to
facilitate the collection, storage, analysis, archiving, and
sharing of data by providing means to connect clinical
phenotype data with disease biology data. It started in
2011 as a Dutch national initiative between CTMM, the
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Dutch Cancer Society, the Dutch Heart Foundation, the
Netherlands Bioinformatics Centre (NBIC), the Parelsnoer
Institute (PSI) and others and developed in the meantime
to a consortium that consists now of 27 partners. The pro-
ject uses already available tools that are integrated into an
IT infrastructure. TraIT will demonstrate the tools Open-
Clinica, XNAT, BBMRI catalogue and TranSMART in
hands-on sessions during this workshop. Already 80 stu-
dies with about 700 users are conducted with OpenClinica
as data management system for clinical trials.
Peter Wittenburg (EUDAT and RDA) introduced
EUDAT, a project that provides common data services for
the entire research community. EUDAT is a collaborative
data infrastructure consisting of a federation of trusted
centres with the focus that its community people are driv-
ing the project. The services available are B2FIND for find-
ing research data, B2SAFE for safely replicating research
data, B2SHARE for storing and sharing research data with
added semantics and B2STAGE for preparing data for
high performance computing. An important aspect of
EUDAT is the Persistent Identifier (PID) service. In princi-
ple, every bit of data may get a PID as a kind of tag when
it enters EUDAT. Another tool is the AAI service offering
secure access to scientific systems. Recently, EUDAT col-
laboration projects have started, with about 30 submis-
sions for participation. ECRIN plans the testing of policy
mechanisms for sensitive data together with EUDAT.
Because big national centres are the actors in EUDAT (e.g.
CSC, SARA, RZG) the sustainability of services is ensured
by agreements.
Niklas Blomberg (EBI) spoke about ELIXIR. ELIXIR
will provide necessary facilities for researchers providing a
multitude of tools required by academics from bench bio-
logists to chemo-informaticians. In this way, it supports
work with the rapidly growing amount of information
about living systems. The ELIXIR infrastructure includes
databases (e.g. ENSEMBL), reference data, tools for data
access, tools for the exchange and analysis of sensitive
data, standards for data exchange, encoding and integra-
tion of data as well as training for researchers. To maintain
core data resources, sustainability plays a role in the pilots
of ELIXIR. The EU genotype / phenotype archive, which
contains individual genomes, has raised the problem of
identifiability of individuals from their genetic information.
As a member of the BioMedBridges project, ELIXIR helps
with a tool for the consistent identification of biosamples
(BioSD) that allows finding and linking 2.8 Mio samples in
32 sources worldwide.
IT challenges for innovative clinical trials
The keynote speech was held by Norbert Graf (USAAR)
about the topic of IT and innovation in clinical trials. In
areas outside clinical trials, IT development has pro-
ceeded to create eBooks and eBanking. In the clinical
trials area such a development is still missing. But as an
example what is already possible, paediatric oncology
can be seen as a success story, where nearly 100% of
patients are able to participate in a clinical trial and
where treatments show striking successes. On the other
hand, still only 5% of adults are enrolled in prospective
clinical trials. In addition, in paediatric oncology, perso-
nalized medicine has become very successful. But perso-
nalized medicine is rather complex requiring many
different kinds of data, even data from system biology
models. The important point is that all necessary patient
data is available for the physician in due time to be used
for clinical decision support. Thus, tool development in
personalized medicine must be clinically driven, evalu-
ated, validated and in a standardised form to allow the
reuse of data. In addition, personal data must be secured
by a security framework (that once being developed can
be re-used for other projects). The use of common ontol-
ogies and semantic mechanisms allow data sharing and
integration and may be shared between projects, too.
The principal investigator may be supported by tools
offering electronic informed consents. But it has to be
considered that often a global informed consent is not
possible, for example in research with biomarkers. In this
case, the investigator has to re-contact the patient to
receive a new right to use biosamples and data for future
research. This situation illustrates the apparent value
conflict that exists between the individual treatment
(privacy protection) and the collective interest (access to
data and research with data). Here a balance has to be
found between both exclusive interests without compro-
mising the transparency for the patient. In this respect,
recent approaches including the ones of PatientsLikeMe,
where patients can upload their clinical data, but where
the personal clinical data belong to the service provider,
who is allowed to sell them for example to insurance
companies, should be avoided. This is not the form of
transparency that will support and improve research.
What is often forgotten is that innovative clinical trials
demand not only novel IT support, but a higher degree of
teamwork between different stakeholders, like infrastruc-
ture providers, legal/ethical people, tool users, trainers,
validation experts, and patients as one additional partner.
Therefore, to concentrate research only on data-driven
approaches will not improve research, but will result in
researchers being lost in data space.
Returning to the p-medicine project, data management
is done with ObTiMA, a tool that has been demonstrated
in this workshop. The experience of the project with soft-
ware development is that in general, tools should be built
in modules, to allow combination of different modules to
adapt to changing requirements, and to ease interoper-
ability between tools. The integration challenge for per-
sonalised medicine data consists in the necessity that
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patient data from different hospital information systems
(HIS) and different push/pull specifications must be con-
sidered and joined. Here, integration can be simplified by
putting HIS data into a standardised data warehouse.
While in the research area it is often possible to use dif-
ferent tools that all are able to access data of patient
cohorts or anonymised medical data, in the area of deci-
sion support only the same tool should be used to ensure
uniformity in decision support. Decision support tools
must also be able to access personal data of a single
patient under conditions of real time constraints. This
gap between basic research and clinical application can
only be closed by interdisciplinary teams.
Break out session 3
In the third demonstration session, tools for clinical
research support (Clinical Trial Information Mediator,
Pathology Reviewer, PASTEL) and EHR associated tools
for clinical data (Query Workbench, Patient recruitment
service) were presented and discussed.
Final joint discussion: conclusions and how can
we achieve sustainability of tools and services?
The first CRI Solutions Day provided an opportunity to
hear from a diverse group of professionals working in
research infrastructure management, clinical trials and
biomedical research about how they cope with the chal-
lenges of new developments in the field. The format of
the workshop consisting of lectures and hands-on ses-
sions of tools with developers was very positively
received; it was appreciated that the focus was on the
developed tools and it was suggested to conduct such a
workshop regularly each year.
The first impression was that EU projects seem to cope
with many similar problems and have come up with simi-
lar solutions. For example, all domains struggle with the
same rigid conditions for data protection and the chal-
lenge of semantic interoperability. Christian Ohmann indi-
cated that several tools address the same problem, for
example four projects developed a query generator. But,
do researchers need this kind of competition? If in such
cases a generic problem exists, it might be better to bring
projects together, work jointly on software development
and increase transparency. Project funding too, should
consider this aspect in EU projects. Peter Wittenburg sug-
gested that researchers in different domains may be able
to use the same tools for their research. In principle, this
problem is also a matter of the funding organisations and
the way projects are supported. On the other hand compe-
tition between projects and the development of similar
solutions may also be a good feature. Norbert Graf argued
that it should be considered that tools developed in EU
projects often grow out of special research questions and
are based on domain specific requirements. Therefore,
project members should compare and examine what
things that can be done together and what can be shared
(e.g. common ontologies used in different disease settings).
Ann Martin agreed about differences in the fundaments of
EU projects and was surprised how different the projects
actually are. Thus, the observed similarity of tools may be
only a resemblance on the surface, but may hide deeper
underlying differences in approaches and requirements.
Töresin Karakoyun took up this remark to address the
problem of sustainability of tools developed in EU projects
suggesting that the next CRI Solutions Day should
be about how to sustain tools and provide support after
the end of a project. It was suggested that industry should
be more involved, perhaps even connections with venture
capital may be helpful to sustain developments. But the
main problem faced by all research projects that develop
tools is the need to shift tool development from the
research area to a setting of professional service provision.
Jacques Demotes stated that sustainability should be an
outcome of a project. Limited ERIC funds are available to
promote a couple of tools that could be part of a clinical
trials tool repository. But in the end, the provision of tools
must generate some revenue to invest in maintenance and
further developments. The infrastructures are learning to
deal with the different challenges; sustainability is one of
these challenges and the many query tools may be part of
the game (Peter Wittenburg). Thus, projects should create
and improve their business models, work together with
stakeholders and funders and tackle the need for seed
money. Though, as was suggested, infrastructures and
projects may share components and tools; it may need
2-3 years for a project to settle a joint understanding to be
able to share.
It followed a discussion of what the business models
of the different tools presented in the break-out ses-
sions were. Several of the tools provide access to
patient data and thus, supply pharma industry
demands. Industry laments the missing access to
patient data; negotiations with hospitals about patient
data often last years. The problem with hospital data
and patient data in general is the restriction of regula-
tions and rules on the use of sensitive data for research
purposes. In the area of patient care and hospitals,
trust in the industry does not exist; and the main con-
cern of data protection officers at hospitals is how any
misuse of data can be absolutely prevented (Christian
Ohmann); an aspect generally overlooked by industry.
To generate this necessary trust, several aspects must
become transparent: the reasons for access to patient
data, who is doing what with the data, and who is
responsible for the data. In the US, insurance compa-
nies are already selling patient data to defined
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questions from industry. In addition, as a consequence
of regulations and rules to protect data privacy the
developed tools must incorporate means for audit trails
and provenance control. In this context, the TRANS-
FoRm project has developed a comprehensive frame-
work to monitor provenance [10]. Nonetheless, to
perform effective health research, systems in hospitals
must open. Patients too are waiting for treatment and
are interested in new research findings and therefore to
a large degree support research with their data. In such
a situation a robust legal framework is needed to
ensure that privacy is protected and that non-anon-
ymised data as well as genetic data is not shared in an
unrestricted way. In fact, laws that forbid physicians to
share such patient data already exist. An extension of
the problem of data confidentiality is that tool develop-
ment in EU projects should not omit the patient
empowerment perspective (Norbert Graf). In the end
data belong to the patient, and often the patient wants
not only to share data but also wants access to data.
Thus, both aspects together, transparency and trust,
are of utmost importance for the development of tools.
Perhaps one should show these problems to policy
makers, to find a way how to overcome them. Ann
Martin pointed out that in fact policy makers have
taken up this topic and are willing to protect patients;
IMI is working on guidelines about secondary use of
treatment data for research.
The final comment, the take home lesson, was stated
by Töresin Karakoyun: 11 EU / IMI projects, 7 research
infrastructures, 22 tools and 92 participants came
together and possibilities for collaboration turned out to
be a focal point for all projects. Collaboration between
research infrastructures and projects can proceed via a
7-stage model moving from simple coexistence and
communication to more intensive cooperation, coordi-
nation and finally to coadunation [11]. At the moment
EU projects are at the point of cooperation and coalition
building, but have not yet reached the possibilities of
true collaboration. To support active collaboration a
kind of platform is needed, to enable collaboration by
providing help to decide how to organize it, how to pay
for it, how to support and maintain it. There should be
rules and guides and a budget for collaboration; technol-
ogy alone is not enough.
Conclusions
The first CRI Solutions Day provided a unique opportu-
nity to see, discuss and evaluate the new tools that soon
will change the way research is done, demonstrated by
the leading research infrastructures and EU projects in
the field of biomedical research. It became clear that
still many challenges exists, especially the sharing and
joining of tools, collaboration and sustainability issues.
Nonetheless, using new tools that will provide advanced
IT support, biomedical research and clinical trials will
become more interesting in future.
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